RESUMEN
BACKGROUND: Home enteral nutrition (HEN) is a safe method for providing nutrition to children with chronic diseases. Advantages of HEN include shorter hospitalizations, lower cost, and decreased risk of malnutrition-associated complications. Follow-up after hospital discharge on HEN is limited. The purpose of this study was to look at children discharged on nasogastric (NG) feeds to assess follow-up feeding status and impact on growth. METHODS: A retrospective chart review was conducted of pediatric patients discharged from Mount Sinai Medical Center on NG feeds between January 2010 and March 2013. RESULTS: A total of 87 patients were included. Average age was 1.2 years. The most common diagnoses were congenital heart disease (47%), metabolic disease (17%), neurologic impairment (10%), liver disease (9%), prematurity (8%), and inflammatory bowel disease (6%). At most recent follow-up, 44 (50.6%) were on full oral feeds, 8 (9.2%) were still on NG feeds, 9 (10.3%) had a gastrostomy tube placed, 9 (10.3%) were deceased, and 17 (19.5%) had transferred care or were lost to follow-up. Average time to discontinuation of NG feeds was 4.8 months. Change in body mass index from hospital discharge to follow-up visit 6 to 12 weeks after discharge was statistically significant, from a mean (SD) of 13.78 (2.82) to 14.58 (2.1) (P = .02). Change in weight z score was significant for neurologic impairment (-1.35 to -0.04; P = .03). Height z score change was significant for prematurity (-3.84 to -3.34; P = .02). There was no significant change in height or weight z scores for the other diagnoses. CONCLUSIONS: NG feeds can help to improve short-term growth after hospital discharge in children with chronic illnesses.
Asunto(s)
Nutrición Enteral/métodos , Intubación Gastrointestinal , Alta del Paciente , Adolescente , Índice de Masa Corporal , Peso Corporal , Niño , Preescolar , Enfermedad Crónica , Femenino , Estudios de Seguimiento , Cardiopatías Congénitas/terapia , Humanos , Lactante , Recien Nacido Prematuro/crecimiento & desarrollo , Enfermedades Inflamatorias del Intestino/terapia , Hepatopatías/terapia , Masculino , Enfermedades Metabólicas/terapia , Enfermedades del Sistema Nervioso/terapia , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
BACKGROUND: Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal tract. Current medications have potentially serious side effects. Hence, there is increasing interest in alternative therapies. We previously demonstrated the anti-inflammatory effects of Food Allergy Herbal Formula-2 in vitro on peripheral blood mononuclear cells (PBMCs) and mucosa from CD subjects. Here, we investigated the anti-inflammatory effects of a bioactive compound isolated from Ganoderma lucidum (G. lucidum), a key herbal constituent of Food Allergy Herbal Formula-2, in CD in vitro. METHODS: Triterpene ganoderic acid C1 (GAC1) was isolated from G. lucidum. Stimulated RAW 264.7 macrophages were treated with GAC1. Human PBMCs and colonic biopsies were obtained from children with CD and cultured with or without GAC1. TNF-α and other proinflammatory cytokine levels were measured in the culture supernatant. NF-κB signaling was investigated in PBMCs and colonic mucosa treated with GAC1 by In-Cell Western and Western blot analysis. RESULTS: GAC1 decreased TNF-α production by macrophages and PBMCs from CD subjects. GAC1 significantly decreased TNF-α, IFN-γ, and IL-17A production by inflamed colonic biopsies from CD subjects. These effects were due to downregulation of the NF-κB signaling pathway. CONCLUSIONS: GAC1 inhibited production of TNF-α and other proinflammatory cytokines by PBMCs and inflamed CD colonic mucosa due to blockage of NF-κB activation. GAC1 is a key beneficial constituent in G. lucidum and the Food Allergy Herbal Formula-2 in suppressing the inflammatory cytokines found in CD and warrants clinical investigation for the treatment of CD.
Asunto(s)
Antiinflamatorios/farmacología , Enfermedad de Crohn/tratamiento farmacológico , Enfermedad de Crohn/metabolismo , Medicamentos Herbarios Chinos , FN-kappa B/metabolismo , Reishi/química , Triterpenos/química , Adolescente , Adulto , Western Blotting , Células Cultivadas , Niño , Colon/citología , Colon/efectos de los fármacos , Colon/metabolismo , Enfermedad de Crohn/patología , Citocinas/metabolismo , Regulación hacia Abajo , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/metabolismo , Macrófagos/citología , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Masculino , Transducción de Señal , Factor de Necrosis Tumoral alfa/metabolismo , Adulto JovenRESUMEN
The aim of this study was to determine the use of complementary and alternative medicine (CAM) in an inflammatory bowel disease population at a single pediatric center. The secondary aims were to determine predictors of CAM use and assess parental attitude to CAM use. A survey was developed that was distributed electronically and given out in the clinic. Two hundred thirty-five surveys were analyzed. Thirty-six percent of respondents reported that their children had used CAM, while 19.6% were current users. Sixty-three percent of respondents were "extremely" or "very supportive" of CAM and 57.6% would have been "extremely" or "very supportive" at the time of their children's diagnosis. The most commonly used CAM modalities were fish oil (48.8%), probiotics (22.5%), acupuncture/pressure (17.5%), aloe (16.3%), yoga/meditation (16.3%), chiropractic (12%), and herbal medicine (13.8%). Multivariate analysis revealed 2 independent factors predictive of subjects using CAM: use of biologics (odds ratio of 2.8; p = .008) and subjects' parent using CAM (odds ratio of 10.9; p ≤ .001). More than one third of children in this study and their parents have used CAM. Families are supportive of CAM both at the time of diagnosis and as an ongoing component of their child's treatment even if they were not past or current users of CAM. Predictors of CAM use were treatment with a biologic and having a parent who used CAM.
Asunto(s)
Terapias Complementarias/estadística & datos numéricos , Enfermedades Inflamatorias del Intestino/terapia , Adolescente , Niño , Femenino , Hospitales Pediátricos , Humanos , Masculino , Padres , Encuestas y CuestionariosRESUMEN
BACKGROUND: Crohn's disease (CD) is a chronic inflammatory disease with increasing incidence in children. Current medications have potentially serious side effects, hence increasing interest in alternative therapies. We previously developed an herbal formula, FAHF-2, based on a classical traditional Chinese herbal formula Wu Mei Wan that has long been used in China to treat colitis. We investigated FAHF-2's potential anti-inflammatory effects. METHODS: FAHF-2 efficacy was tested in vivo in the CD45RbRAG1 transfer colitis model. Weight loss, colonic histology, and cytokine production from mesenteric lymph nodes were assessed. Human peripheral blood mononuclear cells (PBMCs) and colonic biopsies were obtained from children newly diagnosed with CD and controls and cultured with or without FAHF-2. Cytokine levels were measured by multiplex immunoassay. The effect of FAHF-2 on TNF-α-producing cells was determined by flow cytometry. NF-κB signaling was investigated in human lamina propria mononuclear cells upon FAHF-2 treatment by In-Cell Western. RESULTS: FAHF-2-treated mice had decreased weight loss, improved histology, and reduced TNF-α, IL-17, IL-6, and IFN-γ production. In vitro treated PBMCs produced less TNF-α, IFN-γ, and IL-12. FAHF-2 reduced the TNF-α-producing monocytes and T cells. Inflamed CD biopsies produced less TNF-α, IL-17, IL-6, and IL-1ß. These effects are because of decreased NF-κB activation. CONCLUSIONS: FAHF-2 inhibited both adaptive and innate immune proinflammatory cytokine responses in PBMCs and inflamed CD mucosa due in part to blockage of NF-κB activation. FAHF-2 was effective in halting progression of colitis in a murine model. This study shows that FAHF-2 has potential as a novel treatment of CD.
Asunto(s)
Antiinflamatorios/uso terapéutico , Colitis/prevención & control , Colon/efectos de los fármacos , Enfermedades Inflamatorias del Intestino/prevención & control , Leucocitos Mononucleares/efectos de los fármacos , Extractos Vegetales/uso terapéutico , Adolescente , Adulto , Animales , Western Blotting , Estudios de Casos y Controles , Células Cultivadas , Niño , Preescolar , China , Colitis/etiología , Citocinas/metabolismo , Citometría de Flujo , Estudios de Seguimiento , Humanos , Enfermedades Inflamatorias del Intestino/inmunología , Enfermedades Inflamatorias del Intestino/metabolismo , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Macrófagos/metabolismo , Ratones Endogámicos C57BL , Pronóstico , Adulto JovenRESUMEN
BACKGROUND AND OBJECTIVES: Nourishing a child undergoing bone marrow transplant (BMT) is essential, but the optimal method to achieve this is not established. The objectives of the study were to investigate the incidence and risk factors for complications of gastrostomy tubes in patients with BMT. METHODS: A retrospective chart review was conducted of pediatric patients who received a percutaneous endoscopic gastrostomy (PEG) either for BMT or for other indications during a 3-year period. Occurrences of complications, absolute neutrophil count (ANC) at time of PEG placement, and ANC at time of complication were reviewed for both BMT and the comparison group. RESULTS: Of the 11 subjects in the BMT group, 4 (36%) had a major complication of infection related to PEG and 3 of those required PEG removal. Two of the 4 subjects who developed a major complication were moderately neutropenic at the time of PEG placement and all subjects were neutropenic at the time of complication. Of the 30 subjects in the comparison group, only 1 (2.8%) had a major complication with cellulitis. There were no statistically significant differences between the 2 groups before PEG placement for age, weight, albumin, or white blood cell count. The incidence of complication in BMT compared with the comparison group was significant (P=0.01). CONCLUSIONS: Our findings support that ANC should be considered before placement of PEG, significant neutropenia may be a contraindication for PEG placement in BMT patients, and other modalities for nutrition support might need to be considered.
Asunto(s)
Trasplante de Médula Ósea/efectos adversos , Nutrición Enteral/efectos adversos , Gastrostomía/efectos adversos , Complicaciones Posoperatorias/epidemiología , Niño , Preescolar , Remoción de Dispositivos , Femenino , Estudios de Seguimiento , Gastroscopía , Hospitales Universitarios , Humanos , Incidencia , Lactante , Infecciones/epidemiología , Infecciones/inmunología , Masculino , Neutropenia/epidemiología , Neutropenia/inmunología , Ciudad de Nueva York/epidemiología , Complicaciones Posoperatorias/inmunología , Complicaciones Posoperatorias/cirugía , Estudios Retrospectivos , Factores de RiesgoRESUMEN
BACKGROUND: Many treatment options exist for children with inflammatory bowel disease (IBD), yet the lack of clinical guidelines for management has lead to great variation in care. The purpose of this project was to evaluate current treatment modalities in children from the Northeast US who applied to the 2010 session of Camp Oasis, a Crohn's and Colitis Foundation of America (CCFA)-sponsored camp for children ages 8-17 with medically stable IBD. METHODS: Patient demographics, medical history, and current medications were entered into the camp database. The subjects were divided into two groups; Crohn's disease (CD) or ulcerative colitis/indeterminate colitis (UC/IC). In all, 164 applicants were included, 121 (74%) with CD and 43 (26%) with UC/IC. RESULTS: There were no significant differences between the two groups with respect to median age at the time of camp, median age at diagnosis, or median length of illness. Of the 121 applicants with CD, 13 (10.7%) were on an antibiotic, 56 (46.3%) were on a 5-aminosalicylate (5-ASA), 10 (8.3%) were on corticosteroids, 57 (47.1%) were on immunomodulators, and 44 (36.4%) were on a biologic agent. Six (5%) were on both an immunomodulator and a biologic agent. Of the 43 subjects with UC/IC, 27 (62.7%) were on a 5-ASA, two (4.7%) were on corticosteroids, 13 (30.2%) were on an immunomodulator, and four (9.3%) were on a biologic agent. The groups were similar with regard to surgery (20.7% for CD and 18.6% for UC/IC). CONCLUSIONS: Identifying current treatment patterns may serve to highlight variations in care among this pediatric IBD population.
Asunto(s)
Corticoesteroides/uso terapéutico , Colitis Ulcerosa/tratamiento farmacológico , Enfermedad de Crohn/tratamiento farmacológico , Factores Inmunológicos/uso terapéutico , Mesalamina/uso terapéutico , Pautas de la Práctica en Medicina , Adolescente , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Masculino , PronósticoRESUMEN
In pediatrics, growth is considered one of the most important markers of overall well-being. This study looked at growth in children diagnosed with inflammatory bowel disease before they were 5 years old from a single center. The Children's Inflammatory Bowel Disease Center at Mount Sinai maintains a database of 1,150 children followed at the center. Ninety-three children were included in this study, 58% boys and 42% girls. The average age at diagnosis was 3.2 years. Sixty-two percent had ulcerative colitis and 38% had Crohn disease. Height was recorded at initial presentation and at the most recent visit to the center; from this, a height percentile and z score were calculated. A target adult height was calculated for each child on the basis of mid-parental height. This target height was compared to the actual height the children achieved or the percentile they were growing along. Ten percent of children in the study presented with growth failure. For children with early onset ulcerative colitis, 58% achieved or exceeded their projected height percentile. For children with early onset Crohn disease, 38% achieved or exceeded their projected height percentile. Fifty-nine percent of the entire group either maintained their presentation percentile or increased their height percentiles over time, with an increase in z score ranging from 0.093 to 4.137.
Asunto(s)
Colitis Ulcerosa/complicaciones , Enfermedad de Crohn/complicaciones , Trastornos del Crecimiento/etiología , Adolescente , Distribución por Edad , Edad de Inicio , Antropometría , Estatura , Peso Corporal , Niño , Preescolar , Colitis Ulcerosa/diagnóstico , Colitis Ulcerosa/epidemiología , Colitis Ulcerosa/terapia , Enfermedad de Crohn/diagnóstico , Enfermedad de Crohn/epidemiología , Enfermedad de Crohn/terapia , Estudios de Seguimiento , Trastornos del Crecimiento/diagnóstico , Trastornos del Crecimiento/epidemiología , Humanos , Lactante , New York/epidemiología , Estudios Retrospectivos , Índice de Severidad de la EnfermedadRESUMEN
GOALS: Our goals were to answer 2 questions: (1) Is the presentation of early-onset inflammatory bowel disease (IBD) similar to typical adolescent-onset IBD? (2) Is there variability in familial aggregation in childhood IBD? BACKGROUND: The phenotype of IBD in children under 5 years of age (early-onset) is poorly defined. Clinical and genetic studies of IBD, however, generally assume the phenotype to be homogenous throughout childhood. STUDY: We analyzed data from 413 consecutive pediatric IBD outpatients attending our center between 1995 and 2000. Disease type, anatomic distribution, and family history were compared between children presenting before (early-onset) and after the age of five (5 to 15 y). RESULTS: Disease presentation was predominantly colonic in early-onset IBD, most patients presenting with ulcerative colitis (UC). Isolated colonic disease was most frequent in early-onset Crohn disease (colonic 76.5%, ileocolic 24%) compared with ileocolic disease (ileocolic 45.5%, colonic 26%, ileal 19.4%, proximal 6.3%) in the older age group. First-degree family history was highest in early-onset UC 26% versus 11% in the older UC group. CONCLUSIONS: We describe a distinct phenotype of early childhood onset IBD, with a strikingly high familial aggregation in UC and greater tendency to present with colonic disease. As more genetic heterogeneity is identified in IBD, careful definition of phenotype is required to identify further susceptibility genes. The early-onset form of UC presents an ideal group for further genetic analysis. These phenotype differences also suggest that treatment and outcome may vary in early-onset childhood IBD; prospective studies are required to confirm this.
Asunto(s)
Colitis Ulcerosa/genética , Enfermedad de Crohn/genética , Adolescente , Edad de Inicio , Niño , Preescolar , Colitis Ulcerosa/epidemiología , Enfermedad de Crohn/epidemiología , Femenino , Humanos , Lactante , Masculino , Fenotipo , Estudios RetrospectivosAsunto(s)
Hemangioma/enfermería , Cuidados de la Piel/métodos , Neoplasias Cutáneas/enfermería , Úlcera Cutánea/enfermería , Femenino , Hemangioma/clasificación , Hemangioma/complicaciones , Humanos , Recién Nacido , Control de Infecciones/métodos , Resistencia a la Meticilina , Estadificación de Neoplasias , Evaluación en Enfermería , Cuidados de la Piel/instrumentación , Cuidados de la Piel/enfermería , Neoplasias Cutáneas/clasificación , Neoplasias Cutáneas/complicaciones , Úlcera Cutánea/etiología , Infecciones Estafilocócicas/etiología , Infecciones Estafilocócicas/enfermería , Staphylococcus aureus , Infección de Heridas/etiología , Infección de Heridas/enfermeríaRESUMEN
OBJECTIVES: NOD2/CARD15 variants have recently been shown to be associated with Crohn's disease (CD). No analysis of NOD2/CARD15 gene variants has so far been reported in pediatric patients. Therefore, our aim was to analyze NOD2/CARD15 gene variants in children with CD and to perform genotype-phenotype analyses. METHODS: We studied 101 children with CD and 136 healthy controls. Detailed phenotypic information was obtained from each patient. Patients were genotyped for the three NOD2/CARD15 variants R702W (single nucleotide polymorphism 8 [SNP8]), G908R (SNP12), and L1007fs (SNP13), and genotype-phenotype correlations were performed. RESULTS: We found 33 NOD2/CARD15 mutations in 29 of 101 patients (29%). The frequency of NOD2 variation was 31% in white (n=87) compared with 11% in controls (chi2=14; p=0.0001; OR=3.7; 95% CI=1.7-7.8). Four white patients but not control subjects were compound heterozygotes. NOD2/CARD15 variants were significantly associated with ileal disease (chi2=4.5; p=0.03; OR=5; 95% CI=0.9-35.9). Of the children with NOD2/CARD15 variants, 44% were < or =5th percentile for weight at diagnosis, whereas only 15% of children without mutations were < or =5th percentile (chi2=8.7; p=0.003; OR=4.5; 95% CI=1.4-14.4). Similar trends were observed for height but they did not reach statistical significance. CONCLUSIONS: Our results demonstrate that: 1) the three NOD2/CARD15 variants confer risk to CD in children; 2) NOD2/CARD15 variants are associated with ileal disease in children as in adults; and 3) NOD2/CARD15 variants are associated with lower weight percentiles at diagnosis in children and a tendency toward lower height percentile, suggesting an association between growth in children with CD.